

TREATMENT OF HAEMOPHILUS INFLUENZAE MENINGITIS

F. J. SCHULTE and M. VOLLRATH

Department of Pediatrics University of Göttingen

Once every few years new interest in the treatment of the meningitides is revived either since new information about the first choice antibiotics become available, or since follow-up studies reveal that the results are not as good as it is commonly believed. Both is particularly true for *H. influenzae* meningitis.

From several recent publications we know that the mortality can be as high as 17% and ranges probably around 10%, that about 35% may suffer from significant intellectual and/or neurological handicaps, that hearing defects occur in 2—3% of the cases and that the so-called normal survivors are significantly different from matched controls as to their intellectual performance (SPROLES et al. 1969; SELL et al. 1972; GAMSTORP and KLOCKHOFF 1974).

Furthermore, with rigid therapeutic regimes some side effects became apparent which, although rare or even remote, require some second thoughts about risks versus residuals (SCHRÖTER 1974, GAMSTORP and KLOCKHOFF 1974).

The controversy about adequate treatment of *H. influenzae* meningitis again concentrates around the ques-

tion "chloramphenicol versus ampicillin". Neither in vitro (KHAN et al. 1966) nor clinical studies (MATHIES et al. 1965, FLEMING et al. 1965) could find one drug principally superior to the other. This finding is particularly important since sometimes the bacteriocidal effect of ampicillin was discussed against the bacteriostatic effect of chloramphenicol. Theoretically, chloramphenicol has some advantage because of a consistent serum/CSF ratio of about 40% during the whole course of the treatment rather independent from CSF cell count or protein (McCRUMB et al. 1951). CSF ampicillin levels, on the other hand, were found to be more inconsistent and the factors which influence the serum/CSF ratio of this drug are still only partly known: dose, route and interval of administration, CSF protein and meningeal inflammatory reaction, renal function even without clinical signs of failure or diuresis, shock etc. Even if patients with overt renal failure were excluded the CSF values were unpredictable, although with 150—200 mg/kg/day during the first three days of treatment — when cell count and protein were high — "most of the time" sufficient levels were reached

(THRUPP et al. 1965). It is noteworthy, however, that in 12 out of 128 CSF specimens these authors could not detect ampicillin (less than 0,03 mg/ml): two of these patients were treated with ampicillin for meningococcal, four for pneumococcal and six for *H. influenzae* meningitis. In all cases lack of ampicillin in the CSF was also noted during the first three days of treatment, when it is particularly dangerous. Thus, with ampicillin rather high doses of 200—400 mg/kg/day in 4 hours intervals via the i. v. or i. m. route are suggested in order to avoid therapeutic failure (CHERRY and SHEENAN 1968, YOUNG et al. 1968, LEVINE et al. 1970, GREENE 1968, SMITH 1974). However, no significant correlation could be found between CSF drug levels and follow-up studies.

More recently, ampicillin resistant *H. influenzae* have been reported from the US, the United Kingdom and possibly from Germany (CLYMO and HARPER 1974, KHAN et al. 1974, NELSON 1974, SCHIFFER et al. 1974, THOMAS et al. 1974, TOMEH et al. 1974, TURK 1974). "The Committee on Infections of the American Academy of Pediatrics has recently recommended that all systemic infections believed to be caused by *H. influenzae* be treated with chloramphenicol until the organism is shown to be sensitive to ampicillin" (GARDNER 1974). However, sensitivity tests for *H. influenzae* are particularly difficult and not readily available in smaller hospitals (MCLINN et al. 1970).

Because of the reported variance in CSF ampicillin levels we ourselves did never change to ampicillin in the treatment of the meningitides and continued to use double therapy (penicillin and chloramphenicol) in purulent meningitis of unknown origin and chloramphenicol alone in a dose of 100 mg/kg/day, once *H. influenzae* was clearly diagnosed in the cultures. From 1963—1973 twenty-three consecutive cases were thus treated. In the earlier years treatment was continued sometimes as long as 20—25 days. Later, according to international agreement, the drug was discontinued 4 days after the child became afebrile, provided that the CSF cell-count was mononuclear and below 30 per cubic millimeter, that the protein concentration was less than 50 mg/100 ml and that all other signs of an acute inflammatory reaction were disappearing. Thus, the duration of treatment was reduced to less than 15 days. However, we still always exceed the so-called maximum dose of 700 mg/kg chloramphenicol in children with *H. influenzae* meningitis. All our patients were followed both by a pediatric neurologist and a psychologist. From the 23 children only one died (30 minutes after admission), one child, who was admitted 7 days after the onset of the illness has neuro-psychiatric sequelae and only one other has a hearing defect. Thus, 84% of our patients recovered completely. Severe hematologic or other side effects of chloramphenicol were not seen in this hospital.

However, at the moment for some authors it may still not seem justified to treat every purulent meningitis of unknown origin or every *H. influenzae* meningitis with chloramphenicol. The situation becomes again debatable, if Dr. GAMSTORP's (1974) experience with a high percentage of hearing defects after ampicillin therapy of *H. influenzae* meningitis can be demonstrated in a larger series of cases and if ampicillin resistant *H. influenzae* will be found in one's own area. Once can at least make a strong case for chloramphenicol in all those patients with proven or suspected *H. influenzae* meningitis, in which neuropsychiatric symptoms such as apathy or even unconsciousness, convulsions and shock as well as poor meningeal inflammatory reaction do not allow to run any risk of therapeutic delay due to inconsistent CSF drug levels or due to questionable sensitivity of the organism. From the data reported so far no support can be derived for using ampicillin during the first days of treatment and then changing to chloramphenicol, when CSF cell count and protein are such, that the ampicillin concentration in the CSF is likely to be very low. There is strong evidence from the literature, that the efficiency of the treatment during the first days determines the ultimate outcome. Practically all deaths and the major complications occur during the first 3 days. A combination of ampicillin and chloramphenicol is probably dangerous since the two drugs are likely to

be antagonistic (HALTALIN and SMITH 1971).

In this issue of our Journal we asked Dr. LORBER to present his view on the treatment of *H. influenzae* meningitis, which differs somewhat from current practice but, nevertheless, seems to be equally successful.

References

1. CHERRY, J. D. and SHEEMAN, C. P.: Bacteriologic relapse on hemophilus influenzae meningitis. *New England J. of med.* 278, 1001 (1968) - 2. CLYMO, A. B. and HARPER, I. A.: Ampicillin-resistant *Haemophilus influenzae* meningitis. *Lancet* 1, 453 (1974) - 3. FLEMMING, P. C., MURRAY, J. D. M., FUJIWARA, M. W., PRICHARD, J. S. and MCNEUGHTON, G. A.: Ampicillin in the treatment of bacterial meningitis. *Antimicrobial Agents and Chemotherapy* 2, 47 (1966) - 4. GAMSTORP, I. and KLOCKHOFF, I.: Bilateral, severe, sensorineural hearing loss after haemophilus influenzae meningitis in childhood. *Neuropädiatrie* 5, 121 (1974) - 5. GARDNER, P.: Antimicrobial Drug Therapy in Pediatric Practice. *Pediatric Clinics of North America* 21, 617 (1974) - 6. GREENE, H. L.: Failure of ampicillin in meningitis. *Lancet* 1, 861 (1968) - 7. HALTALIN, K. C. and SMITH, J. B.: Reevaluation of ampicillin therapy for Hemophilus influenzae meningitis: An appraisal based on a review of cases of persistent or recurrent infection. *Am. J. Dis. Child* 122, 328 (1971) - 8. KHAN, W., ROSS, S. and ZAREMBA, E. A.: Comparative inhibition of *H. influenzae* by eight antibiotics. *Antimicrobial Agents and Chemotherapy* 6, 393 (1966) - 9. KHAN, W., ROSS, S., RODRIGUEZ, W., CONTRONI, G. and SAZ, A. K.: *Haemophilus influenzae* Type B Resistant to Ampicillin. *J. A. M. A.* 229, 298 (1974) - 10. LEVINE, M. S., BOXERBAUM, B. and HEGGIE, A. D.: Redrudescence of *H. influenzae* meningitis after therapy with ampicillin. *Clinical Pediatrics* 9, 54 (1970) - 11. MATHIES, A. W., LEEDOM, J. M., THRUPE, L. D., IVLER, D., PORTNOY, B. and WEHRLE, P. E.: Experience with ampicillin in

- bacterial meningitis. *Antimicrobial Agents and Chemotherapy* 5, 610 (1965) - 12. McCrumb, F. R., Hall, H. E., Imburg, J., Merideth, A., Helmbold, R.: Treatment of hemophilus influenzae meningitis with chloramphenicol and other antibiotics. *J. A. M. A.* 145, 469 (1951) - 13. McLinn, S. E., Nelson, J. D., Haltalin, K. C.: Antimicrobial susceptibility of Hemophilus influenzae. *Pediatrics* 45, 827 (1970) - 14. Nelson, J. D.: Should Ampicillin Be Abandoned for Treatment of Haemophilus influenzae Disease? *J. A. M. A.* 229, 322 (1974) - 15. Schiffer, M. S., Schneerson, R., MacLowry, J., Robbins, J. B., McReynolds, J. W., Thomas, W. J., Bailey, D. W., Clarke jr., E. J., Mueller, E. J. and Escamilia, J.: Clinical, Bacteriological and Immunological Characterisation of Ampicillin-Resistant Haemophilus Influenzae Type B. *Lancet* 3, 257 (1974) - 16. Schröter, W.: Hematologic side-effects of chloramphenicol. *Neuropädiatrie* 5, 117 (1974) - 17. Sell, S. H. W., Webb, W. W., Pate, J. E. and Doyne, E. O.: Psychological sequelae of bacterial meningitis: Controlled studies. *Pediatrics* 49, 212 (1972) - 18. Smith, A.: Treatment of bacterial meningitis: Antimicrobial and general. *Pediatrics* 53, 597 (1974) - 19. Sproles, E. T., Azerrad, J., Willisamson, C. and Merrill, R. E.: Meningitis due to hemophilus influenzae: Long-term sequelae. *J. Pediat.* 75, 782 (1969) - 20. Thomas, W. J., McReynolds, J. W., Mock, C. R. and Bailey, D. W.: Ampicillin-Resistant Haemophilus Influenzae Meningitis. *Lancet* 23, 313 (1974) - 21. Tomeh, M. O., Stuart, E. S., McGowan, J. E., Terry, P. M. and Nahmias, A. J.: Ampicillin-Resistant Haemophilus influenzae Type B Infection. *J. A. M. A.* 229, 295 (1974) - 22. Thrupp, L. D., Leedom, J. M., Ivler, D., Wehrle, P. F., Portnoy, B. and Mathies, A. W.: Ampicillin levels in the cerebrospinal fluid during treatment of bacterial meningitis. *Antimicrobial Agents and Chemotherapy* 5, 206 (1965) - 23. Turk, D. C.: Ampicillin-resistant Haemophilus influenzae meningitis. *Lancet* 1, 453 (1974) - 24. Young, L. M., Hassow, J. E. and Klein, J. O.: Relapse following ampicillin treatment of acute hemophilus influenzae meningitis. *Pediatrics* 41, 516 (1968).